Contraindications and high-risk medication groups for vorasidenib-VORANIGO

Vorasidenib (trade name VORANIGO) is an oral selective IDH1/IDH2 inhibitor, mainly used to treat carriersLGG) with an>IDH1 or IDH2 mutation. Its mechanism of action is to inhibit the activity of mutant isocitrate dehydrogenase (IDH) and block the accumulation of D-2-hydroxyglutarate (2-HG) in tumor cells, thereby improving cell differentiation and inhibiting tumor proliferation. This precise targeted therapy provides a new treatment option for patients with IDHmutated glioma, but attention must be paid to contraindications and management of high-risk groups during medication to ensure safety.

The main contraindications to vosidenib include patients who are allergic to the drug or excipients. Anaphylaxis may manifest as rash, difficulty breathing, swelling of the face or throat, and in severe cases, anaphylactic shock. Therefore, patients with a known history of drug allergy should be cautious before using vorsidenib and assess the risks under the guidance of a physician. For patients with severe hepatic insufficiency (Child-Pugh C grade), since the drug is mainly metabolized by the liver, the plasma concentration may increase significantly, thereby increasing the risk of adverse reactions. Therefore, these patients are usually not recommended for use or the dose needs to be strictly adjusted.

High-risk drug users mainly include elderly patients, patients with liver and kidney dysfunction, and patients with other chronic diseases. Elderly patients have reduced metabolism and excretion capabilities, and are prone to drug accumulation, which increases the risk of hematology, liver function and gastrointestinal adverse reactions. Patients with hepatic insufficiency need to regularly monitor liver enzyme and bilirubin levels, and adjust the dose or temporarily discontinue the drug if necessary; although patients with renal insufficiency are mainly metabolized by the liver, they still need to pay attention to the potential risks that may arise from blood concentration and accumulation of metabolites. In addition, pregnant and lactating women should avoid using voxirinib. Due to the lack of sufficient human safety data, the drug may have adverse effects on the fetus or newborn. Women of childbearing age should take effective contraceptive measures during treatment.

When using voroxiranib, you also need to pay attention to interactions with other drugs. StrongCYP3A4inhibitors or inducers may significantly change the plasma concentration of vorsidenib, affect the efficacy or increase the risk of adverse reactions. For example, combined use of ketoconazole, clarithromycin, etc.CYP3A4Inhibitors may lead to an increase in blood drug concentration and increase hepatotoxicity or hematological toxicity; while rifampicin, carbamazepine and other CYP3A4 inducers may reduce drug concentration and weaken the efficacy. Therefore, high-risk patients should comprehensively evaluate their past medication history when using voroxiranib, and adjust their medication regimen under the guidance of a physician.

Generally speaking, as a targeted drug for IDH1/IDH2 mutated glioma, vorsidenib has clear efficacy in improving the patient's condition and delaying tumor progression. However, its safe use must be based on a comprehensive assessment of contraindications, liver and kidney function status, high-risk groups and drug interactions. Through scientific management, regular monitoring, timely treatment of adverse reactions, and combined with individualized dose adjustment, vorsidenib can exert its clinical value while ensuring patient safety, and provide an effective and precise treatment plan for patients with IDH mutated glioma.

Reference link:https://www.drugs.com